Lincoln Pharmaceuticals reported FY26 net profit of ₹87.89 crore, up 6.74% YoY, while total income increased 9.10% to ₹704.48 crore. EBITDA rose 5.78% to ₹131.14 crore and EPS stood at ₹43.88. The board recommended a dividend of ₹1.80 per share and the company targets ₹1,000 crore revenue within three years.